8-K current report · filed Nov 3, 2026

Aquestive Therapeutics, Inc. (AQST) 8-K Current Report: November 3, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2AQST overview

Short answer

Aquestive Therapeutics, Inc. (AQST) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Third-quarter results for period ended September 30, 2026 announced.

Aquestive Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Third-quarter results for period ended September 30, 2026 announced
  • Business update included alongside financial results
  • Detailed results and financial schedules available in Exhibit 99.1

Item 7.01 · Regulation FD Disclosure

  • Investor presentation furnished for institutional investor and analyst meetings
  • Presentation may contain updated corporate, pipeline or financial information relevant to AQST valuation
  • Exhibit 99.2 and company investor-relations website provide the substantive disclosure

Item EX-99.1 · Exhibit EX-99.1

  • Anaphylm NDA resubmission accepted as Class 2, with FDA PDUFA goal date March 16, 2027
  • Potential first oral rescue treatment for anaphylaxis, creating meaningful commercial upside if approved
  • Q3 revenue fell 41% to $7.6 million, primarily from timing of Suboxone orders
  • Net loss widened to $16.5 million, while adjusted EBITDA loss increased to $12.2 million
  • Cash $90.3 million at September 30, 2026, with unchanged 2026 revenue guidance of $46 million to $50 million

Item EX-99.2 · Exhibit EX-99.2

  • Anaphylm NDA resubmitted in Q3 2026, with FDA PDUFA goal date March 16, 2027
  • Commercial launch preparations remain on track, but revenue upside depends on FDA approval and market adoption
  • Libervant out-licensing delivered $10 million upfront, with potential $47.5 million milestones and mid-teens net-sales royalties
  • Ending cash declined to $90.3 million in Q3 2026, highlighting funding importance ahead of Anaphylm launch
  • 2026 outlook: revenue approximately $46-$50 million and adjusted EBITDA loss approximately $35-$30 million

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Aquestive Therapeutics, Inc. 8-K filings

Get the next AQST 8-K as it lands

Follow AQST for push alerts, or ask the research agent what this filing means.